Mycobacterium ulcerans vaccine (Swiss TPH Institute/Telormedix)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMycobacterium ulcerans vaccine (Swiss TPH Institute/Telormedix)
Drug Alias NameTMX 201 adjuvant-based Buruli ulcer vaccine - Swiss TPH Institute/TelormedixTMX-201
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsToll-like receptor agonists
TargetsToll-like receptor
Therapy Area/IndicationsUlcerSkin UlcerMalaria, Falciparum
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSwiss Tropical InstituteTelormedix Sa
China Registration ClassN/A

Develop Information

Active CompaniesTelormedix SaSwiss Tropical Institute
Inactive CompaniesN/A
Active IndicationsUlcerSkin UlcerMalaria, Falciparum
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A